PharmaResearch Co., Ltd. (KOSDAQ:214450)

PharmaResearch Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 3, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	4,270,145	2,727,283	1,116,952	697,316	818,025	552,155
Market Cap Growth	74.52%	144.17%	60.18%	-14.76%	48.15%	60.62%
Enterprise Value	3,970,730	2,575,782	990,868	612,568	761,136	536,011
Last Close Price	411000.00	262500.00	109041.14	68996.50	80178.04	55527.18
PE Ratio	28.22	29.63	14.59	17.18	17.52	16.85
Forward PE	19.20	22.06	12.55	10.92	14.49	15.04
PS Ratio	8.61	7.79	4.28	3.58	5.31	5.08
PB Ratio	6.19	4.78	2.42	1.88	2.49	2.09
P/TBV Ratio	6.80	5.38	2.77	2.27	3.10	2.67
P/FCF Ratio	33.94	26.82	21.12	16.55	18.32	-
P/OCF Ratio	26.51	19.75	17.20	11.74	12.53	17.05
EV/Sales Ratio	8.01	7.36	3.80	3.15	4.94	4.93
EV/EBITDA Ratio	18.74	18.44	9.50	8.01	12.27	12.83
EV/EBIT Ratio	20.24	20.43	10.74	9.29	14.50	16.04
EV/FCF Ratio	31.56	25.33	18.74	14.53	17.05	-
Debt / Equity Ratio	0.31	0.37	0.07	0.18	0.20	0.12
Debt / EBITDA Ratio	1.00	1.49	0.33	0.87	1.06	0.78
Debt / FCF Ratio	1.68	2.05	0.65	1.58	1.47	-
Asset Turnover	0.61	0.50	0.52	0.43	0.41	0.37
Inventory Turnover	1.91	1.84	1.90	2.55	2.40	2.07
Quick Ratio	6.55	5.84	2.96	4.04	3.86	2.87
Current Ratio	7.57	6.75	3.89	4.56	4.31	3.55
Return on Equity (ROE)	23.58%	17.23%	18.53%	12.41%	15.80%	13.17%
Return on Assets (ROA)	15.05%	11.33%	11.38%	9.10%	8.78%	7.08%
Return on Capital (ROIC)	16.62%	12.35%	12.34%	9.90%	9.50%	7.65%
Return on Capital Employed (ROCE)	21.90%	16.30%	19.70%	15.60%	13.80%	11.80%
Earnings Yield	3.54%	3.38%	6.85%	5.82%	5.71%	5.94%
FCF Yield	2.95%	3.73%	4.74%	6.04%	5.46%	-0.43%
Dividend Yield	0.27%	0.42%	0.87%	0.96%	0.75%	0.90%
Payout Ratio	7.94%	10.96%	9.84%	15.56%	10.77%	9.04%
Buyback Yield / Dilution	6.08%	2.50%	-5.85%	0.76%	-5.74%	-0.73%
Total Shareholder Return	6.35%	2.92%	-4.97%	1.72%	-4.99%	0.17%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.